{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:52:33Z","timestamp":1777909953592,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The present study was performed to investigate the effect of oral dronabinol, a synthetic tetrahydrocannabinol derivate, on retinal hemodynamics in healthy subjects in a randomized, double-masked, placebo-controlled, 2-way crossover design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Twenty-four subjects received 5\u2009mg dronabinol on 1 study day and placebo on the other study day. Total retinal blood flow (TRBF) was measured using a custom-built Doppler Optical Coherence Tomography system. Oxygen saturation of major retinal vessels was measured with a commercially available Dynamic Vessel Analyzer. Based on these parameters, retinal oxygen extraction was calculated. Measurements were performed before and after drug administration on both study days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Placebo had no effect on TRBF, retinal arterial or venous oxygen content, and retinal oxygen extraction (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&gt;\u20090.1 each). In contrast, dronabinol induced a significant increase in TRBF from 38.9\u2009\u00b1\u20096.1 to 40.7\u2009\u00b1\u20096.7\u2009\u03bcL\/min (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), which was accompanied by a significant increase in retinal venous oxygen content (from 0.129\u2009\u00b1\u20090.008 to 0.132\u2009\u00b1\u20090.009\u2009mL O\n                      <jats:sub>2<\/jats:sub>\n                      \/mL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02). As no change in retinal arterial oxygen content occurred (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.12), retinal oxygen extraction remained stable (2.2\u2009\u00b1\u20090.4\u2009\u03bcL vs. 2.2\u2009\u00b1\u20090.4\u2009\u03bcL O\n                      <jats:sub>2<\/jats:sub>\n                      \/min,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.29).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results indicate that orally administered dronabinol increases TRBF in healthy subjects without altering retinal oxygen extraction. The drug may therefore be a candidate for improving perfusion in patients with ocular vascular disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0131","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:52:10Z","timestamp":1621270330000},"page":"360-366","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Orally Administered Low-Dose Dronabinol on Retinal Blood Flow and Oxygen Metabolism in Healthy Subjects"],"prefix":"10.1177","volume":"37","author":[{"given":"Nikolaus","family":"Hommer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Schmidl","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kallab","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 M.","family":"Werkmeister","sequence":"additional","affiliation":[{"name":"Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopold","family":"Schmetterer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."},{"name":"Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria."},{"name":"Singapore Eye Research Institute, Singapore, Singapore."},{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore."},{"name":"Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore."},{"name":"SERI-NTU Advanced Ocular Engineering (STANCE), Singapore, Singapore."},{"name":"Institute of Molecular and Clinical Ophthalmology, Basel, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marihan","family":"Abensperg-Traun","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Garh\u00f6fer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(00)90646-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/365061a0"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.5.1932"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.25.14565"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1187"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01438-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00259-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2008.07.002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2916732"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053390"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1992.106"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb10916.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3233\/CH-151996"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000097072"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3126\/nepjoph.v10i2.20464"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1797"},{"key":"e_1_3_3_18_2","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=018651 Accessed February12 2021."},{"key":"e_1_3_3_19_2","unstructured":"EMA. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/pips\/EMEA-000643-PIP01-09\/pip_000506.jsp&mid=WC0b01ac058001d129 Accessed February12 2021."},{"key":"e_1_3_3_20_2","first-page":"68","article-title":"(1997)","volume":"28","author":"M\u00fcnster R.D.","year":"1999","unstructured":"M\u00fcnster R.D., , Wittchen H.-U., , Zaudig M., , and Fydrich T. (1997). SKID Strukturiertes Klinisches Interview f\u00fcr DSM-IV. Achse I und II. G\u00f6ttingen: Hogrefe, DM 158. Hiller, W., Zaudig, M. & Mombour, W. (1997). IDCL Internationale Diagnosen Checklisten f\u00fcr DSM-IV und ICD-10. G\u00f6ttingen: Hogrefe, DM 198-bzw. DM 239. Z. Klin. Psychol. Psychother. 28:68\u201370, 1999.","journal-title":"SKID Strukturiertes Klinisches Interview f\u00fcr DSM-IV. Achse I und II. G\u00f6ttingen: Hogrefe, DM 158. Hiller, W., Zaudig, M. & Mombour, W. (1997). IDCL Internationale Diagnosen Checklisten f\u00fcr DSM-IV und ICD-10. G\u00f6ttingen: Hogrefe, DM 198-bzw. DM 239"},{"key":"e_1_3_3_21_2","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32831eef82"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9514"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045876"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.5.000630"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-26234"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.7.34"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep15763"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4309-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18476"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1117\/1.2976032"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7275"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061925"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00622"},{"key":"e_1_3_3_35_2","first-page":"H2085","article-title":"Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current","volume":"276","author":"Gebremedhin D.","year":"1999","unstructured":"Gebremedhin D., , Lange A.R., , Campbell W.B., , Hillard C.J., , and Harder D.R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol. 1999; 276:H2085\u2013H2093.","journal-title":"Am. J. Physiol"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.181"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.02.016"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.07.053"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12560"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(01)00014-3"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.74"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2460"},{"key":"e_1_3_3_43_2","article-title":"Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma","author":"Flach A.J.","year":"2002","unstructured":"Flach A.J. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans. Am. Ophthalmol. Soc. 100:215\u2013222, 2002; discussion 222\u2013214.","journal-title":"Trans. Am. Ophthalmol. Soc"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ijg.0000212260.04488.60"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-197708000-00016"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-019-00978-2"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.03.030"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12854"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.11.003"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:24Z","timestamp":1777646664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8,1]]}},"alternative-id":["10.1089\/jop.2020.0131"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0131","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]}}}